Purpose

This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted to the hospital; and (2) correlate the dynamic changes in eicosanoid mediators with available patient clinical status, including measures of severity of illness, routine laboratory tests, and outcomes.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Admitted to a hospital with symptoms suggestive of COVID-19. 2. Confirmed infection with SARS-CoV-2 as determined by polymerase chain reaction (PCR) or other commercial or public health assay in the 72 hours prior to hospital admission or any time during hospital admission. 3. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 4. Understands and agrees to comply with planned study procedures. 5. Agrees to the collection of whole blood samples.

Exclusion Criteria

  1. Inability to obtain informed consent. 2. Anticipated transfer to another hospital which is not a study site within 48 hours. 3. Inability to obtain sequential blood samples due to patient's characteristics (i.e. difficult vascular access). 4. Obstetric patients. 5. Prisoners.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Recruiting Locations

More Details

NCT ID
NCT04452942
Status
Unknown status
Sponsor
EicOsis Human Health Inc.

Study Contact

Irene Cortes-Puch, MD
3018215857
icortespuch@eicosis.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.